Molecular Partners to Present at Upcoming Healthcare Investor Conference
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced that CEO Patrick Amstutz, Ph.D., will participate in the SVB Leerink 11th Annual Global Healthcare Conference 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced that CEO Patrick Amstutz, Ph.D., will participate in the SVB Leerink 11th Annual Global Healthcare Conference 2022. The presentation is scheduled for February 16, 2022, at 9:20 am ET. This clinical-stage biotech company specializes in developing DARPin therapeutics, a novel class of custom-built protein drugs aimed at addressing healthcare challenges. Their work spans infectious disease, oncology, and ophthalmology, with partnerships among leading pharmaceutical companies.
Details
News Market Reaction – MOLN
The recorded move for MOLN in the trading session of this news was -0.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the SVB Leerink 11th Annual Global Healthcare Conference 2022. The presentation will take place on Wednesday, February 16, at 9:20 am ET.
The webcasted presentation will be made available on the Molecular Partners website.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of infectious disease oncology, and ophthalmology, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.